Bioscience

New Haven-based Trevi Therapeutics Inc. disclosed it is seeking to raise $150 million through a public stock offering to support development of its drug candidate for chronic cough, according to a regulatory filing.

P2 Science has been selected for $2.8 million in federal funding to advance research into faster fuel and chemical production methods.

The investment is in Click Therapeutics, which co-developed an app-based treatment designed to help people with schizophrenia.

Connecticut Innovations announced it has partnered with a global startup accelerator program aimed at supporting early-stage biotechs.

The Connecticut Science Center and Boehringer Ingelheim have launched a new Innovation Lab aimed at expanding STEM education opportunities.

Azitra Inc. has secured up to $31.4 million in private financing as the company works to regain compliance with stock exchange listing requirements.

With scientific researchers learning more about editing human genes to treat rare diseases, a new form of medical treatment has arrived and a new process for approving those treatments is on the horizon.

New Haven-based BioXcel Therapeutics Inc. said it has completed a stock offering that raised about $8 million from an institutional investor.

A state fund that has backed more than 100 Connecticut bioscience startups since 2013 is running low on capital — and lawmakers are weighing whether to refill it.

Intensity Therapeutics, Inc., a Shelton-based biotechnology company, has regained compliance with Nasdaq listing requirements, about three weeks...